KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Mirikizumab Pharmacokinetics and Exposure-Response in Patients With Moderately-To-Severely Active Crohn's Disease: Results From Two Randomized Studies.

Laiyi Chua, Yuki Otani, Zhantao Lin, Stuart Friedrich, Frederick Durand, Xin Cindy Zhang

Clin Transl Sci 18(8) e70320

PMID40804779
PMCIDPMC12350181
DOI10.1111/cts.70320
发表日期2025-08-14
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 multi panel km。
摘要

摘要

Mirikizumab is a humanized anti-interleukin-23-p19 monoclonal antibody approved for both moderately-to-severely active ulcerative colitis and moderately-to-severely active Crohn's disease (CD). We characterized pharmacokinetics (PK) and exposure-response (ER) of mirikizumab in relation to efficacy and safety in CD using data from randomized phase 2 SERENITY (NCT02891226) and phase 3 VIVID-1 (NCT03926130) trials. Patients received 12-week mirikizumab induction (200, 600, or 1000 mg [SERENITY] or 900 mg [VIVID-1] intravenously [IV]) or placebo, every 4 weeks (Q4W), then maintenance (200, 600, or 1000 mg IV [SERENITY], 300 mg subcutaneously (SC) [SERENITY and VIVID-1], or placebo, Q4W) to Week 52. PK and ER for efficacy were analyzed using population PK and logistic regression models for Weeks 12 and 52 endpoints, respectively, and included analyses of covariate effects. Mirikizumab PK was best described by a two-compartment model, with first-order absorption for SC maintenance doses. Body weight, body mass index, serum albumin concentration, C-reactive protein, and disease severity had statistically significant effects on PK, while body weight and disease severity affected ER; these effects were not considered clinically relevant. Efficacy results of 900 mg mirikizumab in VIVID-1 aligned with SERENITY, which observed near-maximal efficacy at Week 12 with 600-1000 mg mirikizumab IV. Efficacy at Week 52 did not vary markedly with exposure during maintenance. There was no significant association between exposure and adverse events. These results support the selection of 900 mg mirikizumab IV Q4W for induction and 300 mg SC Q4W for maintenance in patients with CD, with no dose adjustment for patient factors required.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Box plots of covariate effects on the pharmacokinetics of mirikizumab after IV and SC administration in VIVID‐1. (a) IV C max,ss by weight quartiles, (b) IV C avg,ss by weight quartiles, (c) IV C max,ss by albumin quartiles, (d) IV C avg,ss by albumin quartiles, (e) IV C max,ss by CRP quartiles, (f) IV C avg,ss by CRP quartiles, (g) SC C max,ss by weight quartiles, (h) SC C avg,ss by weight quartiles. The horizontal line in each box represents the median; the top and bottom sides of the box represent the 75th and 25th percentiles, respectively; the whiskers extend to the 95th and 5th percentiles; and circles represent data points outside of the 5th or 95th percentile. C avg,ss , average drug concentration under steady‐state conditions during multiple dosing; C max,ss , maximum concentration during one dosing interval at steady state; CRP, C‐reactive protein; IV, intravenous; Q, quartile; SC, subcutaneous.
非 KM Figure
FIGURE 2FIGURE 2 Relationship between mirikizumab average concentration during the induction period and observed Week 12 response measures in SERENITY and VIVID‐1, stratified by with or without prior biologic failure. (a) Endoscopic response in patients with prior biologic failure. (b) Endoscopic response in patients without prior biologic failure. (c) Clinical response by PRO in patients with prior biologic failure. (d) Clinical response by PRO in patients without prior biologic failure. (e) SES‐CD score change from baseline. (f) CDAI score change from baseline. SERENITY data points represent the percentage of patients who achieved clinical response by PRO in each of the study treatment groups, from left to right: Placebo, 200, 600, and 1000 mg mirikizumab. The points for both SERENITY and VIVID‐1 studies are plotted along the x‐axis at the median time‐averaged concentration ( C avg ) for each cohort. Error bars represent 95% confidence intervals. C avg , average drug concentration under steady state conditions during 1 dosing interval during the induction period; CDAI, Crohn's Disease Activity Index; Pbo, placebo; PRO, Patient‐Reported Outcome; SES‐CD, Simple Endoscopic Score for Crohn's Disease.
非 KM Figure
FIGURE 3FIGURE 3 VIVID‐1 ER relationship plots stratified by median covariate values in both induction and maintenance periods. (a) Endoscopic response at Week 12, stratified by median baseline SES‐CD. (b) Endoscopic response at Week 12, stratified by median baseline BWTV. (c) Clinical response by PRO at Week 12 in patients in VIVID‐1, stratified by median baseline SES‐CD. (d) CDAI clinical remission‐composite at Week 52, stratified by median baseline CDAI. (e) CDAI clinical remission‐composite at Week 52, stratified by median baseline SES‐CD. (f) Endoscopic response‐composite at Week 52, stratified by median baseline SES‐CD. BSESCD, Baseline Simple Endoscopic Score for Crohn's Disease; BWTV, baseline body weight; C avg , average mirikizumab concentration during 1 dosing interval in the induction period; CD, Crohn's disease; CDAI, Crohn's Disease Activity Index; ER, exposure‐response; PI, prediction interval; PRO, Patient‐Reported Outcome; SES‐CD, Simple Endoscopic Score for Crohn's Disease.
非 KM Figure